- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05798338
유방암 환자의 세포밖 소포체 특성 규명
Single Molecule Detection Array (SiMoA) Digital ELISA를 이용한 유방암 환자 혈장 내 세포밖 소포체의 특성 규명
Extracellular vesicles (EVs) are lipid bilayer-delimited particles, naturally released from cells and mediators of intercellular cross-talk. In breast cancer (BC), EVs seem to be involved in the tumor microenvironment's shaping, in cancer cells invasion and in the set-up of metastasis.
Clinical studies have provided initial evidence that these vesicles may have a prognostic and predictive value in breast cancer. Considering their ubiquitous presence in body fluids and their minimally invasive assessment through blood sampling, EVs could have a potential as liquid biopsy-derived biomarkers. Their quantification though is a complex task requiring complicated and time-consuming pre-analytical procedures of EVs isolation.
This protocol want to develop a new method for the detection of tumor-derived-EVs associated proteins, based on the use of Single Molecule Array (SiMoA), a digital ELISA technology able to detect and quantify extremely low concentrations of target proteins or particles.
The aim of this study is to evaluate how this new technology can allow the quantification of EVs plasma levels in patients affected by BC, providing useful diagnostic and prognostic information.
연구 개요
상세 설명
This is a prospective, observational, monocentric and no profit study. The study involves the analysis of plasma from patients with breast cancer in order to quantify and characterize tumor-derived EVs at specific disease stages.
The enrollment of consecutive patients affected by BC referring to an EUSOMA-accredited Breast Unit is planned.
The patients will be divided into three pre-planned groups, as follows:
Population 1: patients diagnosed with early breast cancer patients (stage I-III) with indication to curative surgery.
Population 2: a control group made of sex- and age-matched healthy volunteers, not affected by cancer or chronic diseases.
Population 3: patients with metastatic breast cancer diagnosis. For each patient a blood sample will be collected and plasma will be isolated. A new SiMoA assay based on the use of anti-CD63 and anti-CD9 antibodies, two well known protein markers of EVs, will be used to capture and quantify EVs directly from plasma without requiring any prior sample processing.
The study will be conducted following the International Conference on Harmonization [ICH] Good Clinical Practice [GCP] guidelines. The Ethical Committee of ICS Maugeri authorized the study as protocol 2490/2020.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Fabio Corsi, Professor
- 전화번호: 0382592272
- 이메일: fabio.corsi@icsmaugeri.it
연구 연락처 백업
- 이름: SARA PAOLA ALBASINI, MsC
- 전화번호: 3497378405
- 이메일: sara.albasini@icsmaugeri.it
연구 장소
-
-
Lombardy
-
Pavia, Lombardy, 이탈리아, 27100
- 모병
- Istituti Clinici Scientifici Maugeri SpA
-
연락하다:
- Fabio Corsi, Professor
- 전화번호: 0382592272
- 이메일: fabio.corsi@icsmaugeri.it
-
연락하다:
- Sara Albasini, MsC
- 전화번호: 3497378405
- 이메일: sara.albasini@icsmaugeri.it
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Breast cancer patients
설명
Inclusion Criteria:
- Signing of a specific informed consent for participation to the study
- Female sex
Population 1:
- Diagnosis of early breast cancer;
- Indication for surgery after multidisciplinary discussion.
Population 2:
- Patients having a negative mammography or breast ultrasound within 12 months from the study enrollment.
Population 3:
- Diagnosis of metastatic breast cancer confirmed by cytological/histological examination or by imaging;
- Indication to chemotherapy.
Exclusion Criteria:
Population 1:
- Presence of distant metastases
- Synchronous presence of a different tumor
- Indication to neoadjuvant chemotherapy
Population 2:
- Diagnosis of breast cancer
- Synchronous presence of a different tumor or chronic disease
Population 3:
- Patients who are unfit for systemic chemotherapy treatment
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: CASE_CONTROL
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Early Breast Cancer patients
|
Analysis of plasma in order to quantify and characterize EVs |
|
Metastatic Breast Cancer patients
|
Analysis of plasma in order to quantify and characterize EVs |
|
Healthy patients
- Patients having a negative mammography or breast ultrasound within 12 months from the study enrollment. |
Analysis of plasma in order to quantify and characterize EVs |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
EVs levels in early BC
기간: 36 months
|
Determination of plasma EVs levels in patients with EBC by SIMOA digital ELISA and evaluation of the difference of their concentration compared to healthy controls |
36 months
|
|
EVs levels in metastatic BC
기간: 36 months
|
Determination of plasma EVs levels in patients with first diagnosis of metastatic BC by SIMOA digital ELISA and evaluation of the difference of their concentration compared to healthy controls |
36 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
EVs levels after surgery
기간: 36 months
|
Determination of plasma EVs levels in patients with early BC one month after surgery and comparison with pre-surgery EVs levels in order to evaluate any qualitative of quantitative modifications in circulating EVs |
36 months
|
|
EVs levels after chemotherapy treatment
기간: 36 months
|
Determination of plasma EVs levels in patients with first diagnosis of metastatic BC after 4 months of systemic therapy and comparison with pre-therapy EV's plasma levels |
36 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .